Department of Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15203, USA.
Tissue Eng Part C Methods. 2012 Feb;18(2):133-42. doi: 10.1089/ten.TEC.2011.0305. Epub 2011 Dec 28.
Continuous production of red blood cells (RBCs) in an automated closed culture system using hematopoietic stem cell (HSC) progenitor cell populations is of interest for clinical application because of the high demand for blood transfusions. Previously, we introduced a four-compartment bioreactor that consisted of two bundles of hollow fiber microfiltration membranes for transport of culture medium (forming two medium compartments), interwoven with one bundle of hollow fiber membranes for transport of oxygen (O(2)), carbon dioxide (CO(2)), and other gases (forming one gas compartment). Small-scale prototypes were developed of the three-dimensional (3D) perfusion cell culture systems, which enable convection-based mass transfer and integral oxygenation in the cell compartment. CD34(+) HSC were isolated from human cord blood units using a magnetic separation procedure. Cells were inoculated into 2- or 8-mL scaled-down versions of the previously designed 800-mL cell compartment devices and perfused with erythrocyte proliferation and differentiation medium. First, using the small-scale 2-mL analytical scale bioreactor, with an initial seeding density of 800,000 cells/mL, we demonstrated approximately 100-fold cell expansion and differentiation after 7 days of culture. An 8-mL laboratory-scale bioreactor was then used to show pseudocontinuous production by intermediately harvesting cells. Subsequently, we were able to use a model to demonstrate semicontinuous production with up to 14,288-fold expansion using seeding densities of 800,000 cells/mL. The down-scaled culture technology allows for expansion of CD34(+) cells and stimulating these progenitors towards RBC lineage, expressing approximately 40% CD235(+) and enucleation. The 3D perfusion technology provides an innovative tool for studies on RBC production, which is scalable.
在自动化封闭培养系统中使用造血干细胞(HSC)祖细胞群体连续生产红细胞(RBC),这在临床应用中很有意义,因为对输血的需求很高。此前,我们引入了一种四室生物反应器,它由两组用于培养基运输的中空纤维微滤膜(形成两个培养基室)组成,与一组用于氧气(O(2))、二氧化碳(CO(2))和其他气体运输的中空纤维膜交织在一起(形成一个气体室)。开发了三维(3D)灌注细胞培养系统的小型原型,该系统能够在细胞室中实现基于对流的质量传递和整体供氧。使用磁性分离程序从人脐带血单位中分离 CD34(+) HSC。将细胞接种到以前设计的 800 毫升细胞室设备的 2 毫升或 8 毫升缩小版本中,并以红细胞增殖和分化培养基进行灌注。首先,使用小型 2 毫升分析规模生物反应器,初始接种密度为 800,000 个细胞/mL,我们在培养 7 天后证明了大约 100 倍的细胞扩增和分化。然后使用 8 毫升实验室规模生物反应器通过中间收获细胞来展示伪连续生产。随后,我们能够使用模型来展示使用 800,000 个细胞/mL 的接种密度进行半连续生产,最高可达到 14,288 倍的扩增。缩小规模的培养技术允许 CD34(+)细胞的扩增,并刺激这些祖细胞向 RBC 谱系发展,表达约 40%的 CD235(+)和去核。3D 灌注技术为 RBC 生产研究提供了一种创新工具,具有可扩展性。